James Francis McIntyre, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasm Invasiveness | 1 | 2005 | 3620 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2008 | 2931 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2006 | 4058 | 0.090 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2006 | 243 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2005 | 11878 | 0.070 |
Why?
|
| Amifostine | 1 | 2005 | 40 | 0.060 |
Why?
|
| Radiotherapy Dosage | 3 | 2006 | 2916 | 0.060 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2008 | 329 | 0.060 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2006 | 263 | 0.060 |
Why?
|
| Skull Base Neoplasms | 1 | 2006 | 279 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 899 | 0.050 |
Why?
|
| Photons | 1 | 2006 | 594 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2005 | 1733 | 0.050 |
Why?
|
| Eye Diseases | 1 | 2006 | 660 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 1791 | 0.040 |
Why?
|
| Probability | 1 | 2005 | 2479 | 0.040 |
Why?
|
| Survival Rate | 3 | 2006 | 12840 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2008 | 11244 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 8542 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2005 | 1382 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2006 | 9419 | 0.020 |
Why?
|
| Prognosis | 3 | 2008 | 30010 | 0.020 |
Why?
|
| Survival | 1 | 2008 | 160 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2008 | 65371 | 0.020 |
Why?
|
| Neutrons | 1 | 2006 | 78 | 0.020 |
Why?
|
| Sphenoid Sinus | 1 | 2006 | 101 | 0.020 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2006 | 134 | 0.020 |
Why?
|
| Cavernous Sinus | 1 | 2006 | 121 | 0.020 |
Why?
|
| Filgrastim | 1 | 2005 | 131 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 24315 | 0.010 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2006 | 290 | 0.010 |
Why?
|
| Radiotherapy, Conformal | 1 | 2006 | 549 | 0.010 |
Why?
|
| Carbon | 1 | 2006 | 673 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2005 | 631 | 0.010 |
Why?
|
| Carboplatin | 1 | 2005 | 797 | 0.010 |
Why?
|
| Protons | 1 | 2006 | 1113 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2006 | 1273 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2006 | 1502 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2006 | 794 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 2234 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2006 | 1679 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2005 | 1220 | 0.010 |
Why?
|
| Female | 5 | 2008 | 397192 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 4860 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 6847 | 0.010 |
Why?
|
| Male | 4 | 2008 | 364719 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 4912 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 6514 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2008 | 81762 | 0.010 |
Why?
|
| Aged | 4 | 2008 | 171504 | 0.010 |
Why?
|
| Middle Aged | 4 | 2008 | 223492 | 0.010 |
Why?
|
| Adult | 4 | 2008 | 223646 | 0.010 |
Why?
|
| Humans | 5 | 2008 | 768166 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 59629 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 8741 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 39348 | 0.000 |
Why?
|
| Risk Factors | 1 | 2005 | 74944 | 0.000 |
Why?
|